Andrea Farini

Chiara Villa

Yvan Torrente

Frontiers in Immunology

Directory of Open Access Journals

Frontiers in ImmunologyOPEN ACCESSEDITED AND REVIEWED BYPietro Ghezzi,University of Urbino Carlo Bo, Italy*CORRESPONDENCEYvan Torrenteyvan.torrente@unimi.itRECEIVED 25 July 2024ACCEPTED 12 August 2024PUBLISHED 22 August 2024CITATIONVilla C, Farini A and Torrente Y (2024)Editorial: Inflammation in musculardystrophies: mediators, mechanisms,and therapeutics.Front. Immunol. 15:1470266.doi: 10.3389/fimmu.2024.1470266COPYRIGHT© 2024 Villa, Farini and Torrente. This is anopen-access article distributed under the termsof the Creative Commons Attribution License(CC BY). The use, distribution or reproductionin other forums is permitted, provided theoriginal author(s) and the copyright owner(s)are credited and that the original publicationin this journal is cited, in accordance withaccepted academic practice. No use,distribution or reproduction is permittedwhich does not comply with these terms.TYPE EditorialPUBLISHED 22 August 2024DOI 10.3389/fimmu.2024.1470266Editorial: Inflammation inmuscular dystrophies: mediators,mechanisms, and therapeuticsChiara Villa1, Andrea Farini2 and Yvan Torrente1,2*1Stem Cell Laboratory, Dino Ferrari Center, Department of Pathophysiology and Transplantation,Università degli Studi di Milano, Milan, Italy, 2Neurology Unit, Fondazione IRCCS Ca’ Granda OspedaleMaggiore Policlinico, Milan, ItalyKEYWORDSmiRNA, DMD, muscular dystrophies, inflammation, GHS (growth hormonesecretagogues), NLRP3Editorial on the Research TopicInflammation inmusculardystrophies:mediators,mechanisms, and therapeuticsThe search for effective therapies to treat muscular dystrophies, particularly Duchennemuscular dystrophy (DMD), has been a persistent and formidable challenge. This researchis motivated by the urgent need to address the complex pathophysiology of thesedebilitating diseases, which significantly compromise patients’ quality of life and lifespan.DMD, in particular, poses a substantial challenge due to its progressive nature andsevere impairment of skeletal muscle function. The genetic etiology of the disease,characterized by mutations in the dystrophin gene, initiates a cascade of pathologicalevents, including chronic inflammation.This Research Topic provides innovative therapeutic strategies targeting inflammation inmuscular dystrophies, including the exploration of innate immunity, the therapeutic potential ofgrowth hormone secretagogues, the underlying mechanisms of inflammation-induced muscleatrophy, and the regenerative capabilities of extracellular vesicle-derived miRNAs.Petrof et al. present a compelling case for the involvement of trained immunity in thepathogenesis of DMD, emphasizing the role of dysregulated inflammation mediated byinnate immune cells. Their findings establish a novel framework wherein epigenetic andmetabolic alterations induce a hyper-responsive state in innate immune cells, potentiallyexacerbating tissue damage in DMD.Complementing this perspective, Boccanegra et al. provide preclinical evidencesupporting the therapeutic potential of growth hormone secretagogues (GHS) in DMD.GHSs have demonstrated efficacy in attenuating key drivers of disease progression such asinflammation and fibrosis, and concomitantly exhibited beneficial effects on musclefunction and metabolism, suggesting a multifaceted therapeutic potential for improvingthe quality of life in DMD patients.In parallel, Liu et al. explore the intricate relationship between inflammation andskeletal muscle atrophy, particularly in the context of sepsis-induced complications. Theirinvestigation of the NLRP3 inflammasome reveals a critical role in driving catabolicprocesses, implicating it as a potential target for mitigating muscle wasting andassociated comorbidities.frontiersin.org01Villa et al. 10.3389/fimmu.2024.1470266Finally, Yedigaryan et al. highlight the therapeutic potential ofextracellular vesicle-derived miRNAs in muscle wasting conditions.Through a comprehensive analysis, they identify a hypertrophicmiRNA signature capable of enhancing myogenic capacity andattenuating muscle degeneration. This promising approach holdssignificant implications to stimulate muscle repair and function.In conclusion, the presented studies underscore the imperativefor a multidisciplinary approach to address the challenges posed byDMD. The synergy between basic research, clinical studies, anddrug development is essential for identifying novel therapeuticstrategies and improving patient quality of life.Author contributionsYT: Writing – review & editing. CV: Writing – original draft.AF: Writing – original draft.Frontiers in Immunology 02Conflict of interestThe authors declare that the research was conducted in theabsence of any commercial or financial relationships that could beconstrued as a potential conflict of interest.The author(s) declared that they were an editorial boardmember of Frontiers, at the time of submission. This had noimpact on the peer review process and the final decision.Publisher’s noteAll claims expressed in this article are solely those of the authorsand do not necessarily represent those of their affiliated organizations,or those of the publisher, the editors and the reviewers. Any productthat may be evaluated in this article, or claim that may be made by itsmanufacturer, is not guaranteed or endorsed by the publisher.frontiersin.org

Editorial: Inflammation in muscular dystrophies: mediators, mechanisms, and therapeutics

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1470266/pdf

Editorial: Inflammation in muscular dystrophies: mediators, mechanisms, and therapeutics

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals